JUMBO-TIMI-26-Studie
Abbildung 3: Ergebnisse der JUMBO-TIMI-26-Studie (p < 0,05: signifikant; MACE: "major adverse cardiac event" nach 30 Tagen; MI: Myokardinfarkt nach 30 Tagen;
CTVT: "clinical target vessel thrombosis" nach 30 Tagen. Mod. nach [Wiviott S, Antman E, Winters K, Weerakkody G, Murphy S, Behounek B, Carney R, Lazzam C, McKay R, McCabe C, Braunwald E; JUMBO TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist,
with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization
of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation
2005; 111: 3366–73.])
Keywords:
Diagramm,
JUMBO-TIMI-26-Studie,
Kardiologie